Literature DB >> 10874494

Role of alpha v integrins during angiogenesis.

B P Eliceiri1, D A Cheresh.   

Abstract

Angiogenesis depends on specific molecular interactions between vascular cells and components of the extracellular matrix. This review focuses on the recent advances in the understanding of the mechanism of action of integrins and integrin antagonists during angiogenesis. For example, angiogenesis induced with vascular endothelial growth/permeability factor but not with basic fibroblast growth factor (bFGF) depends on integrin avb5 and Src kinase activity. In contrast, bFGF-induced angiogenesis requires integrin avb3 and functions independently of Src. Recent studies document a role for integrins and growth factor regulation of Src family kinases during angiogenesis. We also discuss the effect of av integrin antagonists on angiogenesis during tumor growth, inflammatory disease, and retinopathy and summarize recent clinical progress in using av integrin antagonists.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10874494

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  45 in total

1.  Adipose tissue-derived stem cells display a proangiogenic phenotype on 3D scaffolds.

Authors:  Evgenios A Neofytou; Edwin Chang; Bhagat Patlola; Lydia-Marie Joubert; Jayakumar Rajadas; Sanjiv S Gambhir; Zhen Cheng; Robert C Robbins; Ramin E Beygui
Journal:  J Biomed Mater Res A       Date:  2011-05-31       Impact factor: 4.396

2.  Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span.

Authors:  Riccardo E Nisato; Jillian A Harrison; Raphaele Buser; Lelio Orci; Chris Rinsch; Roberto Montesano; Philippe Dupraz; Michael S Pepper
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

Review 3.  Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?

Authors:  Roland Haubner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

4.  Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA.

Authors:  Md Rowshon Alam; Xin Ming; Michael Fisher; Jeremy G Lackey; Kallanthottathil G Rajeev; Muthiah Manoharan; Rudy L Juliano
Journal:  Bioconjug Chem       Date:  2011-07-20       Impact factor: 4.774

5.  Angiogenesis blockade as a new therapeutic approach to experimental colitis.

Authors:  Silvio Danese; Miquel Sans; David M Spencer; Ivy Beck; Fernando Doñate; Marian L Plunkett; Carol de la Motte; Raymond Redline; David E Shaw; Alan D Levine; Andrew P Mazar; Claudio Fiocchi
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

Review 6.  Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades.

Authors:  Livija Deban; Carmen Correale; Stefania Vetrano; Alberto Malesci; Silvio Danese
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

Review 7.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Netrin-1 specifically enhances cell spreading on fibronectin in human glioblastoma cells.

Authors:  Hyun Kyoung Lee; In Ae Seo; Yoon Kyung Shin; Sang Hwa Lee; Su-Young Seo; Duk Joon Suh; Hwan Tae Park
Journal:  Korean J Physiol Pharmacol       Date:  2008-10-31       Impact factor: 2.016

9.  Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model.

Authors:  Y Jeffrey Wu; Leslie L Muldoon; Seymur Gahramanov; Dale F Kraemer; Deborah J Marshall; Edward A Neuwelt
Journal:  J Neurooncol       Date:  2012-07-29       Impact factor: 4.130

10.  Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.

Authors:  Ryogo Minamimoto; Amer Karam; Mehran Jamali; Amir Barkhodari; Sanjiv Sam Gambhir; Oliver Dorigo; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.